{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:37:40Z","timestamp":1791005860993,"version":"4.1.0"},"reference-count":239,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pharmr.2025.100060","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T18:58:45Z","timestamp":1745607525000},"page":"100060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Innovative therapeutics for renoprotection: Where we are"],"prefix":"10.1016","volume":"77","author":[{"given":"Monica","family":"Cortinovis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Perico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmr.2025.100060_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2019.11.022","article-title":"In a phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure","volume":"97","author":"Abumoawad","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100060_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.pharmr.2025.100060_bib6","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib7","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20233411B1c","article-title":"AYAME study: Randomized, double-blind, placebocontrolled phase 3 study of bardoxolone methyl in diabetic kidney disease (DKD) patients","volume":"34","author":"Akizawa","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pharmr.2025.100060_bib9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100060_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","article-title":"Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?","volume":"46","author":"Ando","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmr.2025.100060_bib11","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"ASTRAL Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors","volume":"37","author":"Auerbach","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.pharmr.2025.100060_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1681\/ASN.2017101062","article-title":"Should we increase GFR with bardoxolone in Alport syndrome?","volume":"29","author":"Baigent","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib14","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines","volume":"7","author":"Barber","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharmr.2025.100060_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J Pers Soc Psychol"},{"key":"10.1016\/j.pharmr.2025.100060_bib17","article-title":"Updated interim results of a phase \u00bd study of BION-1301 in patients with IgA nephropathy","volume":"8","author":"Barratt","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-150-12-200906160-00119","article-title":"Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial","volume":"150","author":"Bax","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-020-04518-2","article-title":"Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition","volume":"36","author":"Benigni","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ki.1993.263","article-title":"A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression","volume":"44","author":"Benigni","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100060_bib22","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100060_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41581-025-00931-8","article-title":"Risk-directed management of chronic kidney disease","volume":"21","author":"Blum","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib25","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmr.2025.100060_bib26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib27","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15961","article-title":"NRF2 in kidney physiology and disease","volume":"12","author":"Bondi","year":"2024","journal-title":"Physiol Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.pharmr.2025.100060_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100794","article-title":"Structural and functional insights into aldosterone synthase interaction with its redox partner protein adrenodoxin","volume":"296","author":"Brixius-Anderko","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100060_bib31","article-title":"When origin matters: properties of mesenchymal stromal cells from different sources for clinical translation in kidney disease","volume":"8","author":"Calcat-I-Cervera","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharmr.2025.100060_bib32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1600-6143.2012.04115.x","article-title":"Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation","volume":"12","author":"Casiraghi","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12015-011-9345-4","article-title":"Multipotent mesenchymal stromal cell therapy and risk of malignancies","volume":"9","author":"Casiraghi","year":"2013","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmr.2025.100060_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/ijms18040783","article-title":"Emerging roles of IL-33\/ST2 axis in renal diseases","volume":"18","author":"Chen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100060_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fcell.2019.00285","article-title":"Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients","volume":"7","author":"Cheng","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.pharmr.2025.100060_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100060_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2215\/CJN.0000000000000338","article-title":"Targeting APRIL in the treatment of IgA nephropathy","volume":"19","author":"Cheung","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmr.2025.100060_bib40","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000445844","article-title":"Progression, remission and regression of chronic renal diseases","volume":"134","author":"Cortinovis","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.pharmr.2025.100060_bib43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib44","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib45","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100060_bib47","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100060_bib48","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100060_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.109.132670","article-title":"Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease","volume":"54","author":"Dhaun","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100060_bib51","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100060_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MNH.0000000000000513","article-title":"Novel therapeutic strategies for renovascular disease","volume":"28","author":"Eirin","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmr.2025.100060_bib54","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/stem.1047","article-title":"Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis","volume":"30","author":"Eirin","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmr.2025.100060_bib55","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1038\/s41598-017-08726-z","article-title":"Administration of mesenchymal stromal cells before renal ischemia\/reperfusion attenuates kidney injury and may modulate renal lipid metabolism in rats","volume":"7","author":"Erpicum","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib56","first-page":"85","article-title":"Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway","volume":"30","author":"Fang","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib59","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","article-title":"Mitigating risk of aldosterone in diabetic kidney disease","volume":"29","author":"Frimodt-M\u00f8ller","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmr.2025.100060_bib61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib62","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib63","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib65","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100060_bib67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semnephrol.2015.02.004","article-title":"Endothelin and the renal microcirculation","volume":"35","author":"Guan","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100060_bib69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.10.027","article-title":"Metabolomics and gene expression analysis reveal down-regulation of the citric acid (TCA) cycle in non-diabetic CKD patients","volume":"26","author":"Hallan","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmr.2025.100060_bib70","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","article-title":"Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation","volume":"18","author":"Heerspink","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2025.100060_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.716","article-title":"IL-33 Inhibition with tozorakimab for diabetic kidney disease: a randomized, placebo-controlled phase 2b study","volume":"39","author":"Heerspink","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib72","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib73","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib74","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib75","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib76","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib77","first-page":"1035","article-title":"Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury","volume":"14","author":"Herrera","year":"2004","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fped.2016.00053","article-title":"Long-term outcomes of childhood onset nephrotic syndrome","volume":"4","author":"Hjorten","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.pharmr.2025.100060_bib79","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ekir.2024.03.009","article-title":"Inhibition of interleukin-33 to reduce glomerular endothelial inflammation in diabetic kidney disease","volume":"9","author":"Hofherr","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib80","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1021\/acs.jmedchem.2c00834","article-title":"Discovery of SPH3127: a novel, highly potent, and orally active direct renin inhibitor","volume":"65","author":"Iijima","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100060_bib81","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acsmedchemlett.6b00251","article-title":"Discovery of TAK-272: a novel, potent, and orally active renin inhibitor","volume":"7","author":"Imaeda","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.pharmr.2025.100060_bib82","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJMe2413288","article-title":"Way stations in progress\u2014burgeoning treatment options for IgA nephropathy","volume":"392","author":"Ingelfinger","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib83","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100060_bib84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.07720618","article-title":"Efficacy and safety of imarikiren in patients with type 2 diabetes and microalbuminuria: a randomized, controlled trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib85","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib86","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib87","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib88","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/096368915X688173","article-title":"Infusion of human bone marrow-derived mesenchymal stem cells alleviates autoimmune nephritis in a lupus model by suppressing follicular helper T-cell development","volume":"25","author":"Jang","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib90","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1161\/CIRCRESAHA.119.315180","article-title":"Glucose 6-phosphate accumulates via phosphoglucose isomerase inhibition in heart muscle","volume":"126","author":"Karlstaedt","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2025.100060_bib92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pharmr.2025.100060_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pharmr.2025.100060_bib94","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC Review Topic of the Week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib95","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100060_bib97","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib98","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49998","article-title":"The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: a trial protocol","volume":"7","author":"Kotwal","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharmr.2025.100060_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.pharmr.2025.100060_bib100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2019.03.004","article-title":"Refractory lupus nephritis: When, why and how to treat","volume":"18","author":"Kronbichler","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.pharmr.2025.100060_bib101","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib102","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN Randomized Clinical Trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100060_bib103","doi-asserted-by":"crossref","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib104","article-title":"Mesenchymal stem\/stromal cell-based therapies in systemic rheumatic disease: from challenges to new approaches for overcoming restrictions","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100060_bib105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100060_bib106","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib107","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib108","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib109","article-title":"Immunomodulatory activity of mesenchymal stem cells in lupus nephritis: advances and applications","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2025.100060_bib110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","article-title":"Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes","volume":"98","author":"Li","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmr.2025.100060_bib112","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/SHK.0000000000000080","article-title":"Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice","volume":"41","author":"Luo","year":"2014","journal-title":"Shock"},{"key":"10.1016\/j.pharmr.2025.100060_bib114","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.intimp.2013.05.031","article-title":"Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration","volume":"17","author":"Lv","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmr.2025.100060_bib116","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib117","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib118","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib119","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.pharmr.2025.100060_bib120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib121","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bcpt.13050","article-title":"Pharmacokinetics, pharmacodynamics and safety of a single dose of imarikiren, a novel renin inhibitor, in healthy male subjects","volume":"123","author":"Matsuno","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharmr.2025.100060_bib122","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib123","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100060_bib124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/rccm.201705-1006OC","article-title":"Cellular immunotherapy for septic shock. A phase I clinical trial","volume":"197","author":"McIntyre","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.pharmr.2025.100060_bib126","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib127","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100060_bib128","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100060_bib129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13287-022-03112-7","article-title":"First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome","volume":"13","author":"Morello","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.pharmr.2025.100060_bib130","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1634\/stemcells.2007-0795","article-title":"Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice","volume":"26","author":"Morigi","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmr.2025.100060_bib131","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u201calarmin\u201d?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100060_bib133","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100060_bib134","article-title":"Diabetic ketoacidosis with SGLT2 inhibitors","volume":"371","author":"Musso","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100060_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003461","article-title":"Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression","volume":"17","author":"Musso","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib136","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib137","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI Study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib138","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib139","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100060_bib140","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100060_bib141","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100060_bib142","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib143","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib144","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib145","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib146","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib147","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","article-title":"Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study","volume":"12","author":"Packham","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmr.2025.100060_bib148","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.0000000000000300","article-title":"SGLT2 inhibition and kidney potassium homeostasis","volume":"19","author":"Palmer","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib149","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib150","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib151","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib152","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib153","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-017-0356-x","article-title":"The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse","volume":"43","author":"Pasini","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100060_bib154","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ddr.21760","article-title":"Role of mineralocorticoid receptor antagonists in kidney diseases","volume":"82","author":"Patel","year":"2021","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.pharmr.2025.100060_bib155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib156","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1681\/ASN.2017070781","article-title":"Clinical translation of mesenchymal stromal cell therapies in nephrology","volume":"29","author":"Perico","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib157","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib158","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib159","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib160","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib161","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"91","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib162","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib163","article-title":"Mesenchymal stromal cell therapy in solid organ transplantation","volume":"11","author":"Podest\u00e0","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2025.100060_bib164","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib165","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib166","article-title":"Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: results of a phase I clinical trial","volume":"70","author":"Ranjbar","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib167","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1681\/ASN.2012050457","article-title":"Bardoxolone methyl decreases megalin and activates nrf2 in the kidney","volume":"23","author":"Reisman","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib168","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1681\/ASN.V4140","article-title":"Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes","volume":"4","author":"Remuzzi","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib169","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100060_bib170","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib171","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib172","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib173","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12882-023-03339-3","article-title":"UK Kidney Association Clinical Practice Guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE","volume":"24","author":"Roddick","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib174","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100060_bib175","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib176","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib177","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib178","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000529471","article-title":"The CARDINAL trial of bardoxolone methyl in Alport syndrome: when marketing interests prevail over patients clinical needs","volume":"147","author":"Ruggenenti","year":"2023","journal-title":"Nephron"},{"key":"10.1016\/j.pharmr.2025.100060_bib179","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000045998","article-title":"Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion","volume":"88","author":"Ruggenenti","year":"2001","journal-title":"Nephron"},{"key":"10.1016\/j.pharmr.2025.100060_bib180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib181","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib182","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: the neglected issue of residual proteinuria","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib183","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib184","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, regression of chronic renal diseases","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.kint.2020.07.036","article-title":"Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice","volume":"99","author":"Rush","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib186","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1681\/ASN.2017020151","article-title":"Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease","volume":"28","author":"Saad","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib187","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100060_bib188","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100060_bib189","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib190","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.123.21716","article-title":"Endothelin system in hypertension and chronic kidney disease","volume":"81","author":"Schiffrin","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100060_bib191","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100060_bib192","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib193","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib194","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmr.2025.100060_bib195","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(05)60275-9","article-title":"Giuseppe Remuzzi: dreaming of no more renal dialysis","volume":"352","author":"Simini","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib196","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib197","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib198","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmr.2025.100060_bib199","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmr.2025.100060_bib200","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2016101150","article-title":"Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery","volume":"29","author":"Swaminathan","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib201","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1681\/ASN.2014121274","article-title":"Paradigm shifts in atherosclerotic renovascular disease: where are we now?","volume":"26","author":"Textor","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib203","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pharmr.2025.100060_bib205","doi-asserted-by":"crossref","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib206","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2012.08.034","article-title":"Kidney protection and regeneration following acute injury: progress through stem cell therapy","volume":"60","author":"T\u00f6gel","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmr.2025.100060_bib207","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data","volume":"97","author":"Tomazos","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib208","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 Inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100060_bib209","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100060_bib210","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100060_bib211","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.pharmr.2025.100060_bib212","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib214","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100060_bib215","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100060_bib216","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 Exploratory Analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.pharmr.2025.100060_bib217","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmr.2025.100060_bib218","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib219","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169424","article-title":"A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome","volume":"8","author":"Vivarelli","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmr.2025.100060_bib220","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100060_bib221","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","article-title":"A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus","volume":"10","author":"Wang","year":"2018","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib222","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib223","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","volume":"39","author":"Wanner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2025.100060_bib224","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2215\/CJN.02400222","article-title":"Effects of bardoxolone methyl in Alport syndrome","volume":"17","author":"Warady","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib225","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.27688","article-title":"Platform clinical trials for the efficient evaluation of multiple treatments","author":"Webb","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100060_bib226","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharmr.2025.100060_bib227","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of complement dysregulation-an overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.pharmr.2025.100060_bib228","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100060_bib229","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib230","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib231","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1507\/endocrj.EJ22-0123","article-title":"Therapeutic role of mesenchymal stem cells (MSCs) in diabetic kidney disease (DKD)","volume":"69","author":"Xu","year":"2022","journal-title":"Endocr J"},{"key":"10.1016\/j.pharmr.2025.100060_bib232","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41581-023-00683-3","article-title":"Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup","volume":"19","author":"Zarbock","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib233","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100060_bib234","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmr.2025.100060_bib235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmr.2025.100060_bib236","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.592233","article-title":"Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases \u03b1-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib237","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100060_bib238","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1097\/01.ASN.0000034912.55186.EC","article-title":"How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach","volume":"13","author":"Zoja","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100060_bib239","doi-asserted-by":"crossref","first-page":"F808","DOI":"10.1152\/ajprenal.00376.2012","article-title":"Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects","volume":"304","author":"Zoja","year":"2013","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972507468X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972507468X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:55:41Z","timestamp":1759964141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972507468X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":239,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S003169972507468X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100060","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative therapeutics for renoprotection: Where we are","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100060"}}